Tumor necrosis factor alpha -238G/A (rs 361525) gene polymorphism predicts progression to type-2 diabetes in an Eastern Indian population with prediabetes

Diabetes Research and Clinical Practice

Volumn 99, Issue 3, 2013, Pages

  Dutta, Deep ^a   Choudhuri, Subhadip ^a   Mondal, Samim Ali ^a   Maisnam, Indira ^a   Reza, Abu Hena Hasanoor ^a   Ghosh, Sujoy ^a   Chowdhury, Subhankar ^a   Bhattacharya, Basudev ^a   Mukhopadhyay, Satinath ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

IL6 174 G C polymorphism; Insulin resistance; Prediabetes; TNF 238 G A polymorphism; TNF 308 G A polymorphism

Indexed keywords

GLUCOSE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE COURSE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INDIAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDIABETIC STATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876182574     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.12.007     Document Type: Article

References (18)

1. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V. Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006, 49:289-297.
2. Feinstein R., Kanety H., Papa M.Z., Lunenfeld B., Karasik A. Tumour necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993, 268:26055-26058.
3. Eizirik D.L., Cardozo A.K., Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29:42-61.
4. Guzmán-Flores J.M., Muñoz-Valle J.F., Sánchez-Corona J., Cobián J.G., Medina-Carrillo L., García-Zapién A.G., et al. Tumor necrosis factor-alpha gene promoter -308G/A and -238G/A polymorphisms in Mexican patients with type 2 diabetes mellitus. Dis Markers 2011, 30:19-24.
5. Hedayati M., Sharifi K., Rostami F., Daneshpour M.S., Zarif Yeganeh M., Azizi F. Association between TNF-α promoter G-308A and G-238A polymorphisms and obesity. Mol Biol Rep 2012, 39(February):825-829.
6. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
7. Levy J.C., Matthews D.R., Hermans MP Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998, 21:2191-2192.
8. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
9. Paine S.K., Sen A., Choudhuri S., Mondal L.K., Chowdhury I.H., Basu A., et al. Association of tumor necrosis factor α, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects. Retina 2012, 32:1197-1203.
10. Chui M.H., Papanikolaou Y., Fontaine-Bisson B., Turcotte J., Wolever T.M., El-Sohemy A., et al. The TNF-alpha -238G> a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes. Behav Neurosci 2007, 121:619-624.
11. Dalziel B., Gosby A.K., Richman R.M., Bryson J.M., Caterson I.D. Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002, 10:401-407.
12. Kubaszek A., Pihlajamäki J., Komarovski V., Lindi V., Lindström J., Eriksson J., et al. Finnish diabetes prevention study promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2003, 52:1872-1876.
13. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
14. Lindholm E., Bakhtadze E., Cilio C., Agardh E., Groop L., Agardh C.D. Association between LTA, TNF and AGER polymorphisms and late diabetic complications. PLoS ONE 2008, 3:e2546.
15. Wang Y., Ng M.C., So W.Y., Ma R., Ko G.T., Tong P.C., et al. Association between tumour necrosis factor-alpha G-308A polymorphism and risk of nephropathy in obese Chinese type 2 diabetic patients. Nephrol Dial Transplant 2005, 20:2733-2738.
16. Walston J., Seibert M., Yen C.J., Cheskin L.J., Andersen R.E. Tumor necrosis factor-alpha-238 and -308 polymorphisms are not associated with traits related to obesity and insulin resistance. Diabetes 1999, 48:2096-2098.
17. Testa R., Olivieri F., Bonfigli A.R., Sirolla C., Boemi M., Marchegiani F., et al. Interleukin-6-174 G>C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 71:299-305.
18. Huth C., Heid I.M., Vollmert C., Gieger C., Grallert H., Wolford J.K., et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 2006, 55:2915-2921.